公开(公告)号：US20160161485A1

公开(公告)日：2016-06-09

申请号：US14930603

申请日：2015-11-02

申请人： GENENTECH, INC.

发明人： Felix CHU ,  Oded FOREMAN ,  James ZIAI

IPC分类号： G01N33/569 ,  C07K16/28 ,  A61K38/17 ,  G01N33/58 ,  C12Q1/06

CPC分类号： G01N33/56972 ,  A61K38/177 ,  C07K16/2875 ,  C07K2317/24 ,  C07K2317/75 ,  C12Q1/06 ,  G01N33/57419 ,  G01N33/582 ,  G01N2333/70514 ,  G01N2800/52 ,  G01N2800/7028

摘要： The present disclosure provides methods for measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing cancer cells and lymphocytes obtained from a subject by labeling lymphocytes that show CD4 expression in the sample, then labeling lymphocytes that show OX40 expression in the sample, then labeling lymphocytes that show Foxp3 expression in the sample, then measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample. Further provided are methods for determining the prognosis of a subject, predicting responsiveness of a subject having cancer to an OX40 agonist treatment, and methods for treating or delaying progression of cancer based on the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample.

摘要翻译： 本公开提供了通过标记在样品中显示CD4表达的淋巴细胞，然后标记在样品中表现出OX40表达的淋巴细胞，测量含有从受试者获得的癌细胞和淋巴细胞的样品中CD4 + OX40 + Foxp3 +淋巴细胞数目的方法， 在样品中显示Foxp3表达的淋巴细胞，然后测量样品中CD4 + OX40 + Foxp3 +淋巴细胞的数量。 还提供了用于确定受试者的预后的方法，预测具有癌症的受试者对OX40激动剂治疗的反应性，以及基于样品中CD4 + OX40 + Foxp3 +淋巴细胞数量来治疗或延缓癌症进展的方法。

公开(公告)号：US20210109099A1

公开(公告)日：2021-04-15

申请号：US17075520

申请日：2020-10-20

申请人： Genentech, Inc.

发明人： Felix CHU ,  Oded FOREMAN ,  James ZIAI

IPC分类号： G01N33/569 ,  G01N33/574 ,  A61K38/17 ,  C07K16/28 ,  C12Q1/06 ,  G01N33/58

摘要： The present disclosure provides methods for measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing cancer cells and lymphocytes obtained from a subject by labeling lymphocytes that show CD4 expression in the sample, then labeling lymphocytes that show OX40 expression in the sample, then labeling lymphocytes that show Foxp3 expression in the sample, then measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample. Further provided are methods for determining the prognosis of a subject, predicting responsiveness of a subject having cancer to an OX40 agonist treatment, and methods for treating or delaying progression of cancer based on the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample.